What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 3.8% in the afternoon session after ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year ...

Myriad Genetics, the company that once held patents on human genes, is now suing two rivals who are conducting gene tests using its other patents not banned by the Supreme Court.

Looking at Myriad Genetics’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Gilead Sciences delivered year-on-year ...

Puneet Souda has given his Buy rating due to a combination of factors including the successful transformation of Myriad Genetics and its solid performance in the recent quarter. The company not ...

Myriad Genetics employed 2,662 people as of 2023, including 68 international employees working from Austria, France, Germany, Japan and Switzerland.

It looks like the courts have finally put an end to Myriad Genetics' attempts to monopolize our genes. Following decisions striking down its gene patents from the U.S. Supreme Court, a Utah federal ...

Despite Myriad Genetics’ bullish stance on their ability to maintain average selling prices (ASPs) and the expectation of a 12% or higher compound annual growth rate (CAGR) in revenue from 2024 ...

Myriad Genetics is down 13% since the beginning of the year, and at $11.74 per share, it is trading 59% below its 52-week high of $28.60 from September 2024. Investors who bought $1,000 worth of ...

Myriad Genetics is up 10.7% during the same time and is heading into earnings with an average analyst price target of $20.09 (compared to the current share price of $14.35).